Anesiva Completes Enrollment in Phase III Trial of Zingo

Anesiva announced that it has completed enrollment in a Phase III clinical study of Zingo to reduce pain associated with peripheral venous access procedures in adults.

Zingo (lidocaine hydrochloride monohydrate) was approved by FDA Aug. 16 to reduce the pain associated with venous access procedures in children ages three to 18.

According to Anesiva, the Phase III study has enrolled 699 patients undergoing intravenous cannulation or venipuncture procedures at multiple clinical centers in the U.S. Patients were randomized to receive treatment with either Zingo or placebo approximately one to three minutes prior to the peripheral venous access procedure.

The company said it expects to announce results from the trial in October.